Skip to main content

Table 1 Summarization of clinico-pathologic factors of entire patients and according to the subgroups stratified by the cholesterol level of 170 mg/dL cut-off

From: Preoperative cholesterol level as a new independent predictive factor of survival in patients with metastatic renal cell carcinoma treated with cyto-reductive nephrectomy

 

Entire patients (n = 244)

High PCL group (n = 72)

Low PCL group (n = 172)

p value

Median (IQR) or Number (percent)

Age (y)

59.0 (52.0–68.0)

57.5 (52.0–67.0)

60.0 (51.3–68.8)

0.981

BMI (kg/m 2)

23.0 (21.0–24.8)

23.5 (21.8–42.8)

22.9 (20.8–24.9)

0.239

Sex (male)

185 (75.8%)

50 (69.4%)

135 (78.5%)

0.091

Serum Albumin (g/dL)

4.0 (3.5–4.3)

4.3 (3.9–4.4)

3.9 (3.4–4.2)

< 0.001

Hemoglobin (g/dL)

12.1 (10.6–13.6)

13.1 (11.7–14.7)

11.8 (10.3–13.1)

< 0.001

Platelet (k/dL)

274.5 (132.3–173.8)

271.5 (212.5–320.5)

299.8 (222.0–378.8)

0.038

PLC (mg/dL)

156.0 (132.3–173.8)

190 (178–205.8)

139.1 (126.3–157.8)

 

Corrected calcium (mg/dL)

9.2 (8.9–9.7)

9.4 (9.0–9.8)

9.5 (8.8–9.6)

 

ECOG score (≥2)

79 (32.4%)

22 (30.6%)

57 (33.1%)

0.765

Diabetes mellitus

60 (24.7%)

14 (19.7%)

46 (26.7%)

0.326

Hypertension

120 (49.6%)

33 (46.5%)

87 (50.9%)

0.574

Tumor size (cm)

8.0 (5.6–10.5)

6.5 (5.0–9.5)

8.7 (6.1–11.0)

0.407

Clinical stage (≥3)

138 (56.6%)

32 (44.4%)

106 (61.6%)

0.059

Metastatic sites

   

0.541

 Lung

78 (32.0%)

23 (31.9%)

55 (32.0%)

 

 Liver

7 (2.7%)

1 (1.4%)

5 (2.9%)

 

 Bone

24 (9.8%)

10 (13.9%)

14 (8.1%)

 

 Non-regional LNI

2 (1.0%)

0 (0%)

2 (1.2%)

 

 Adrenal gland

8 (3.3%)

4 (5.6%)

4 (2.3%)

 

 Multiple metastasis

10 (4.1%)

3 (4.2%)

7 (4.1%)

 

 Information missing

108 (44.3%)

33 (45.8%)

75 (43.6%)

 

 Miscellaneous

2 (1.0%)

0 (0%)

2 (1.2%)

 

Pathologic stage

   

0.060

 pT1

60 (24.6%)

24 (33.3%)

36 (20.9%)

 

 pT2

36 (14.8%)

11 (15.3%)

25 (14.5%)

 

 pT3

117 (48.0%)

33 (45.8%)

84 (48.8%)

 

 pT4

31 (12.7%)

4 (5.6%)

27 (15.7%)

 

Fuhrman grade

   

0.424

  ≤ 2

34 (13.9%)

12 (16.7%)

22 (12.8%)

 

  ≥ 3

210 (86.1%)

60 (83.3%)

150 (87.2%)

 

Histologic subtype

   

0.214

 Clear cell

213 (87.3%)

67 (93.1%)

146 (84.9%)

 

 Papillary

13 (5.3%)

2 (2.8%)

11 (6.4%)

 

 Chromophobe

4 (1.6%)

0 (0%)

4 (2.3%)

 

 Collecting duct

5 (2.0%)

1 (1.4%)

4 (2.3%)

 

 Unclassified

9 (3.7%)

2 (2.8%)

7 (4.1%)

 
  1. IQR interquartile range, PCL preoperative cholesterol level, BMI body mass index, ECOG Eastern Cooperative Oncology Group, LNI lymph node invasion